摘要
目的:通过网状Meta分析,评价不同口服中成药辅助常规疗法治疗糖尿病心肌病的疗效差异。方法:计算机检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、the Cochrane Library和Embase数据库中口服中成药辅助治疗糖尿病心肌病的随机对照试验(RCT)研究,检索时限为建库以来至2022年4月26日,按照纳入、排除标准筛选文献并提取资料,对文献进行质量评价后,通过Stata 15.0软件完成数据分析。结果:最终纳入28项研究,涉及13种中成药,共2019例受试者。统计结果显示,在总有效率方面,最佳的3种干预措施为常规治疗联合麝香保心丸>常规治疗联合灯盏生脉胶囊>常规治疗联合通心络胶囊;在提高射血分数方面,最佳的3种干预措施为常规治疗联合灯盏生脉胶囊>常规治疗联合麝香保心丸>常规治疗联合通心络胶囊;在提高左心室舒张早期充盈峰值流速与左心室舒张晚期充盈峰值流速的比值方面,最佳的3种干预措施为常规治疗联合益心舒胶囊>常规治疗联合麝香保心丸>常规治疗联合通心络胶囊。结论:中成药辅助治疗糖尿病心肌病效果良好,期待开展更多大样本、多中心、高质量的RCT研究。
OBJECTIVE:To evaluate the efficacy difference of different oral Chinese patent medicine in the treatment of diabetic cardiomyopathy through network Meta-analysis.METHODS:CNKI,Wanfang Data,VIP,CBM,PubMed,the Cochrane Library and Embase databases were retrieved to collect the randomized controlled trials(RCT)of oral Chinese patent medicine in adjuvant treatment of diabetic cardiomyopathy.The retrieval time was from the establishment of the database to Apr.26th,2022.According to inclusion and exclusion criteria,literature was screened and data were extracted.After literature quality evaluation,data analysis was completed by Stata 15.0 software.RESULTS:Twenty-eight studies were enrolled,including 13 kinds of Chinese patient medicines and 2019 patients.In terms of total effective rate,the optimized three interventions were conventional treatment combined with Shexiang Baoxin pills>conventional treatment combined with Dengzhan Shengmai capsules>conventional treatment combined with Tongxinluo capsules.In terms of increasing ejection fraction,the optimized three interventions were conventional treatment combined with Dengzhan Shengmai capsules>conventional treatment combined with Shexiang Baoxin pills>conventional treatment combined with Tongxinluo capsules.In terms of increasing the ratio of early diastolic peak flow velocity to late diastolic peak flow velocity,the optimized three interventions were conventional treatment combined with Yixinshu capsules>conventional treatment combined with Shexiang Baoxin pills>conventional treatment combined with Tongxinluo capsules.CONCLUSIONS:The efficacy of oral Chinese patent medicine in adjuvant treatment of diabetic cardiomyopathy is significant.More large-sample,multi-center,high-quality RCT are expected to be conducted.
作者
张吉航
刘德山
宋民
邢兆艺
ZHANG Jihang;LIU Deshan;SONG Min;XING Zhaoyi(School of Traditional Chinese Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,China;Dept.of Traditional Chinese Medicine,Qilu Hospital of Shandong University,Jinan 250012,China)
出处
《中国医院用药评价与分析》
2023年第6期723-730,共8页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
刘德山山东省名老中医药专家传承工作室建设项目(No.2019-92-19)
齐鲁医派老年病中西汇通学术流派传承工作室项目(No.2022-93-1-10)。
关键词
糖尿病心肌病
口服中成药
网状Meta分析
中医药
Diabetic cardiomyopathy
Oral Chinese patent medicine
Network Meta-analysis
Chinese patent medicine
